Cogentix Medical 10-Q 12 Nov 13 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Sep. 30, 2013	Nov. 04, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'VISION SCIENCES INC /DE/	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--03-31	'
Entity Common Stock, Shares Outstanding	'	46,354,852
Amendment Flag	'false	'
Entity Central Index Key	'0000894237	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net sales	$3,968	$3,739	$7,620	$7,135
Cost of sales	2,773	2,669	5,345	5,152
Gross profit	1,195	1,070	2,275	1,983
Selling, general, and administrative expenses	2,050	3,164	5,100	5,894
Research and development expenses	428	527	847	1,014
Operating loss	-1,283	-2,621	-3,672	-4,925
Interest income	1	1	1	2
Interest expense	-44	-237	-85	-431
Other, net	6	-35	2	-40
Debt cost expense	'	-128	'	-272
Loss on extinguishment of debt	'	-1,244	'	-1,244
Loss before provision for income taxes	-1,320	-4,264	-3,754	-6,910
Income tax provision	3	'	3	1
Net loss	($1,323)	($4,264)	($3,757)	($6,911)
Net loss per common share - basic and diluted (in Dollars per share)	($0.03)	($0.09)	($0.08)	($0.15)
Weighted average shares used in computing net loss per common share - basic and diluted (in Shares)	46,144	45,974	46,127	45,827

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) (USD $)	Sep. 30, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$455	$788
Accounts receivable, less allowances of $94 and $113, respectively	2,815	3,624
Inventories, net	5,683	5,158
Prepaid expenses and other current assets	393	276
Total current assets	9,346	9,846
Machinery and equipment	3,449	3,489
Demo equipment	1,260	1,101
Furniture and fixtures	225	225
Leasehold improvements	372	372
Property and equipment, at cost	5,306	5,187
Less—accumulated depreciation and amortization	3,996	3,733
Total property and equipment, net	1,310	1,454
Other assets, net	77	77
Total assets	10,733	11,377
Current liabilities:	'	'
Accounts payable	1,188	1,300
Accrued expenses	778	728
Accrued compensation	560	656
Deferred revenue	153	130
Capital lease obligations	46	75
Total current liabilities	2,725	2,889
Convertible debt—related party	20,000	17,000
Deferred revenue, net of current portion	61	62
Capital lease obligations, net of current portion	'	22
Total liabilities	22,786	19,973
Commitments and Contingencies	'	'
Stockholders’ deficit:	'	'
Common stock, $0.01 par value Authorized—75,000 shares; issued and outstanding—46,414 shares and 46,249 shares, respectively	464	463
Additional paid-in capital	101,146	100,819
Treasury stock at cost, 59 shares and 34 shares of common stock, respectively	-78	-50
Accumulated deficit	-113,585	-109,828
Total stockholders’ deficit	-12,053	-8,596
Total liabilities and stockholders’ deficit	$10,733	$11,377

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $)	Sep. 30, 2013	Mar. 31, 2013
In Thousands, except Share data, unless otherwise specified
Accounts receivable, allowances (in Dollars)	$94	$113
Preferred Stock Par Value (in Dollars per share)	$0.01	$0.01
Preferred Stock, Authorized Shares (in Shares)	5,000,000	5,000,000
Preferred Stock, Shares Issued (in Shares)	0	0
Preferred Stock, Shares Outstanding (in Shares)	0	0
Common Stock, Par Value (in Dollars per share)	$0.01	$0.01
Common Stock, Authorized Shares (in Shares)	75,000,000	75,000,000
Common Stock, Shares Issued (in Shares)	46,414,000	46,249,000
Common Stock, Shares Outstanding (in Shares)	46,414,000	46,249,000
Treasury Stock, Shares (in Shares)	59,000	34,000

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Stockholders’ Deficit (Unaudited) (USD $)	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Total
In Thousands
Balance at Mar. 31, 2013	$463	$100,819	($50)	($109,828)	($8,596)
Balance (in Shares) at Mar. 31, 2013	46,249	'	34	'	46,249
Issuance of restricted stock awards	1	-1	'	'	'
Issuance of restricted stock awards (in Shares)	165	'	'	'	'
Common stock repurchased	'	'	-28	'	-28
Common stock repurchased (in Shares)	'	'	25	'	'
Stock-based compensation expense	'	328	'	'	328	[1]
Net loss	'	'	'	-3,757	-3,757
Balance at Sep. 30, 2013	$464	$101,146	($78)	($113,585)	($12,053)
Balance (in Shares) at Sep. 30, 2013	46,414	'	59	'	46,414
[1]	Reflects reversal of stock-based compensation expense of $289 thousand for the cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari.

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013		Sep. 30, 2012
Cash flows from operating activities:	'		'
Net loss	($3,757)		($6,911)
Adjustments to reconcile net loss to net cash used in operating activities:	'		'
Depreciation and amortization	362		406
Stock-based compensation expense	328	[1]	1,012
Provision for (recovery of) bad debt expenses	7		-7
(Gain) loss on disposal of fixed assets	-5		44
Debt cost expense	'		272
Loss on extinguishment of debt	'		1,244
Changes in assets and liabilities:	'		'
Accounts receivable	802		-600
Inventories	-712		-752
Prepaid expenses and other current assets	-117		-99
Accounts payable	-112		588
Accrued expenses	50		-303
Accrued compensation	-96		190
Deferred revenue	22		-7
Advances from customers	'		-529
Net cash used in operating activities	-3,228		-5,452
Cash flows from investing activities:	'		'
Purchases of property and equipment	-46		-55
Proceeds from disposal of fixed assets	3		5
Net cash used in investing activities	-43		-50
Cash flows from financing activities:	'		'
Proceeds from issuance of convertible debt—related party	3,000		'
Proceeds from promissory note—related party	'		5,000
Net proceeds from sale of common stock	'		878
Proceeds from exercise of stock options	'		85
Common stock repurchased	-28		-24
Payments of capital leases	-34		-48
Net cash provided by financing activities	2,938		5,891
Net (decrease) increase in cash and cash equivalents	-333		389
Cash and cash equivalents at beginning of period	788		2,674
Cash and cash equivalents at end of period	455		3,063
Cash paid during the period for:	'		'
Interest	4		585
Income taxes	3		7
Non-cash financing activities:	'		'
Net transfers of inventory to fixed assets for use as demonstration equipment	$187		$91
[1]	Reflects reversal of stock-based compensation expense of $289 thousand for the cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari.

Note_1_Summary_of_Significant_

Note 1. Summary of Significant Accounting Policies	6 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Note 1. Summary of Significant Accounting Policies
	Vision-Sciences, Inc. and its subsidiaries (the “Company,” or “our”, “us” or “we”) designs, develops, manufactures, and markets products for endoscopy – the science of using an instrument, known as an endoscope, to provide minimally invasive access to areas not readily visible to the human eye. Our products are sold throughout the world through direct sales representatives in the United States (“U.S.”) and independent distributors for the rest of the world. With respect to our urology products, we are the exclusive supplier to the Endoscopy Division of Stryker Corporation (“Stryker”). Our largest geographic markets are the U.S. and Europe.
	We are incorporated in Delaware, and are the successor to operations begun in 1987. In December 1990, Machida Incorporated (“Machida”) became our wholly-owned subsidiary. We own the trademarks Vision SciencesTM and Slide-OnTM and the registered trademarks EndoSheath®, EndoWipe® and The Vision System®. Not all products referenced in this report are approved or cleared for sale, distribution, or use.
	Basis of Presentation and Preparation
	We have prepared the condensed consolidated financial statements included herein according to generally accepted accounting principles in the United States of America (“U.S. GAAP”), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and include, in the opinion of management, all adjustments that we consider necessary for a fair presentation of such information. We have condensed or omitted certain information and footnote disclosures normally included in financial statements pursuant to those rules and regulations. We believe, however, that our disclosures are adequate to make the information presented not misleading.
	The results for the interim periods presented are not necessarily indicative of results to be expected for the full fiscal year. Please read these condensed consolidated financial statements in conjunction with the consolidated financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2013.
	Liquidity and Capital Resources
	We have incurred substantial operating losses since our inception and there can be no assurance that we will ever achieve or sustain a profitable level of operations in the future. We anticipate negative cash flows from operations during the remainder of fiscal 2014, driven by continued investment in a direct sales force for the U.S. market, spending for marketing, spending for research and development, and general business operations. As of September 30, 2013, we had cash and cash equivalents totaling approximately $0.5 million. We expect that our cash at September 30, 2013, together with the $3.5 million of capital available as of September 30, 2013 under a revolving convertible promissory note dated September 25, 2013 (the “2013 Note”) and up to $5.0 million of capital to be made available to us, subject to certain conditions and an expiration date of July 1, 2014, under a letter agreement dated June 21, 2013 with Lewis C. Pell, our Chairman (the “Letter Agreement”) (see Note 5. Convertible Debt – Related Party for additional information), should be sufficient to fund our operations through at least September 30, 2014. However, if our performance expectations fall short (including our failure to generate expected levels of sales) or our expenses exceed expectations, or if the commitments under the 2013 Note or the Letter Agreement become unavailable, we will need to secure additional financing and/or reduce our expenses to continue our operations. Our failure to do so would have a material adverse impact on our prospects and financial condition. There can be no assurance that any contemplated additional financing will be available on terms acceptable to us, if at all. If required, we believe we would be able to reduce our expenses to a sufficient level to continue to operate as a going concern.
	Summary of Significant Accounting Policies
	Our condensed consolidated financial statements are prepared in accordance with U.S. GAAP. These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable, based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. To the extent there are any differences (other than nominal differences) between these estimates, judgments or assumptions and actual results, our financial statements will be affected.
	The accounting policies that reflect our more significant estimates, judgments, and assumptions and that we believe are the most critical to aid in fully understanding and evaluating our reported financial results include the following:
	• Revenue recognition;
	• Stock-based compensation expense;
	• Allowances for doubtful accounts;
	• Inventory obsolescence and realization;
	• Fair value measurements of convertible debt – related party;
	• Obligations under warranties; and
	• Other contingencies.
	The accompanying condensed consolidated financial statements reflect the accounts of the Company. All significant inter-company accounts and transactions have been eliminated in consolidation.
	Fair Value Measurements
	The carrying amounts reflected in our condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued expenses, accrued compensation, and capital lease obligations approximate fair value due to their short-term nature. The fair value of our convertible debt – related party is based on its face value, which is equal to its carrying value.
	In determining the fair value of the convertible debt – related party, we analyzed its attributes (coupon rate, conversion price, and the percentage of market cap the face value of the debt instrument was prior to the announcement of the debt) to public company convertible debt issuances from June 2011 through September 2012 (a sixteen (16) month period) in the healthcare industry. We determined the convertible debt was not issued at a discount as its fair value was equal to its face (carrying) value.
	Concentration of Credit Risk
	Concentration of credit risk with respect to accounts receivable relates to certain domestic and international customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, when appropriate, we obtain advance payments for our international sales. As a consequence, we believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses, but historically we have not experienced any significant credit losses related to any individual customer or group of customers in any particular industry or geographic area.
	The following table summarizes net sales to our significant customers, which accounted for more than 10% of total segment net sales and total accounts receivable, net:
		Three Months Ended						Six Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Medical segment
	Stryker	$	1,201		$	395		$	2,346		$	1,008
	Percentage of total segment net sales		35	%		15	%		36	%		19	%
	Percentage of total net sales		30	%		11	%		31	%		14	%
	Percentage of total accounts receivable, net		36	%		11	%
	Industrial segment
	Pratt & Whitney, a division of United Technology Corporation	$	31		$	426		$	66		$	706
	Percentage of total segment net sales		5	%		42	%		6	%		37	%
	Percentage of total net sales		1	%		11	%		1	%		10	%
	Percentage of accounts receivable, net		1	%		16	%

Note_2_Basic_and_Diluted_Net_L

Note 2. Basic and Diluted Net Loss per Common Share	6 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	Note 2.     Basic and Diluted Net Loss per Common Share
	Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding. For all periods presented, the diluted net loss per common share is the same as basic net loss per common share, as the inclusion of other shares of stock issuable pursuant to stock options, warrants, and convertible debt would be anti-dilutive.
	The following table summarizes equity securities that were excluded from the calculation of fully diluted loss per share as of September 30, 2013 and 2012.
		September 30,
		2013		2012
	Convertible debt		16,666,666		12,500,000
	Stock options		4,506,775		6,291,179
	Warrants		1,880,620		1,880,620
	Restricted stock		207,902		177,150
	Total anti-dilutive securities		23,261,963		20,848,949

Note_3_Inventories

Note 3. Inventories	6 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	Note 3. Inventories
	Inventories are stated at the lower of cost or market using the first-in, first-out (“FIFO”) method and consist of the following:
		September 30,		March 31,
		2013		2013
	Raw materials	$	4,465	$	4,352
	Work in process		602		427
	Finished goods		616		379
	Inventories, net	$	5,683	$	5,158
	Raw materials include components purchased from independent suppliers. Most purchased components are available from multiple sources, with the exception of certain key components which are supplied to us by key suppliers, with whom we have long-term supply arrangements, but no long-term supply agreements.

Note_4_Supply_Agreement

Note 4. Supply Agreement	6 Months Ended
	Sep. 30, 2013
Deferred Revenue Disclosure [Abstract]	'
Deferred Revenue Disclosure [Text Block]	'
	Note 4. Supply Agreements
	Under a three-year agreement with Stryker expiring in April 2014, we are the exclusive supplier of Stryker-branded flexible video and fiber cystoscopes. These cystoscopes employ our patented EndoSheath technology, which are co-branded Stryker and Vision-Sciences. We also supply Stryker with flexible ureteroscopes under an agreement expiring in December 2015. Until the expiration dates noted, Stryker has the exclusive rights to distribute products we manufacture, including cystoscopes, urology EndoSheath technology, and ureteroscopes, in North America, South America, Latin America, China, and Japan. Although Stryker was to receive the exclusive rights for the rest of the world in April 2012, we reached an agreement with Stryker to delay this launch indefinitely.
	We also have a development and supply agreement with SpineView, Inc. (“SpineView”) under which we developed and supply a charge-coupled device (CCD) based video surgical endoscope for use with SpineView’s products. In December 2012, SpineView received 510(k) clearance from the U.S. Food and Drug Administration (the “FDA”) to use our system for spine applications. With this clearance and the units supplied from the initial stocking order of 50 SpineView surgical endoscope systems, the balance of which was fulfilled during fiscal 2013, SpineView continues to conduct clinical preference trials for minimally invasive spine surgeries. As a result, we do not anticipate any sales to SpineView during the remainder of fiscal 2014.
	We received advances from Stryker for future orders and from SpineView for the initial stocking order. All of the advances were fully utilized as of September 30, 2012.

Note_5_Convetible_Debt_Related

Note 5. Convetible Debt - Related Party	6 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	Note 5. Convertible Debt – Related Party
	Convertible Promissory Notes
	On September 25, 2013 (the “Effective Date”), we entered into the 2013 Note with Mr. Pell. The 2013 Note accrues annual interest, payable annually, at the rate of 1.66%. The 2013 Note must be repaid in full on or before the fifth anniversary of the Effective Date (the “Maturity Date”), but may be prepaid by us at any time without penalty. We will be required to repay all amounts outstanding under the 2013 Note upon an event of default, as defined in the 2013 Note. As we draw upon the 2013 Note, a beneficial conversion feature will be recorded if the market price of our common stock increases after the Effective Date. From the Effective Date to September 30, 2013, the conversion price of the 2013 Note was below the market price of our common stock.
	The outstanding principal amount of the 2013 Note is convertible at any time prior to the Maturity Date, at Mr. Pell’s option, into shares of our common stock at a price of $0.89, the closing bid price of our common stock on the Effective Date. At September 30, 2013, we did not have any outstanding principal borrowings under the 2013 Note.
	On September 19, 2012 (the “Replacement Note Effective Date”), we entered into a $20.0 million revolving convertible promissory note (the “Replacement Note”) with Mr. Pell. The Replacement Note (i) consolidated and restructured the $15.0 million in aggregate borrowings collectively outstanding under an Amended and Restated Loan Agreement, dated September 30, 2011, between us and Mr. Pell (the “Original Agreement”) and a separate promissory note, dated July 25, 2012, between us and Mr. Pell, and (ii) provided for up to $5.0 million in additional borrowings.
	The Replacement Note accrues annual interest, payable annually, at the rate of 0.84%. The Replacement Note must be repaid in full on or before the fifth anniversary of the Replacement Note Effective Date (the “Replacement Note Maturity Date”), but may be prepaid by us at any time without penalty. We will be required to repay all amounts outstanding under the Replacement Note upon an event of default, as defined in the Replacement Note.
	The outstanding principal amount of the Replacement Note is convertible at any time prior to the Replacement Note Maturity Date, at Mr. Pell’s option, into shares of our common stock at a conversion price of $1.20 per share, which was the closing bid price of our common stock on the Replacement Note Effective Date. At September 30, 2013, we had $20.0 million in outstanding principal borrowings under the Replacement Note, which is reflected as convertible debt – related party on our condensed consolidated balance sheet.
	Pursuant to the Original Agreement, Mr. Pell received warrants to purchase an aggregate of 1,880,620 shares of our common stock at a weighted average exercise price of $1.86 per share. All of the warrants are vested and expire on the later of September 30, 2016 or one year after the termination of the Original Agreement and repayment of all amounts due and payable under the Original Agreement.
	In connection with the issuance of the Replacement Note and the termination of the Original Agreement, we determined that the transaction should be classified as an extinguishment of debt. Accordingly, we wrote-off the remaining deferred debt cost balance of $1.2 million at September 19, 2012.
	We estimated the fair value of all of the stock warrants issued on the date of vesting using a Black-Scholes valuation model that used the weighted average assumptions for the risk-free interest rate, expected life (in years), and expected volatility. We recorded the transaction as a deferred debt cost and amortized to expense over the term of the loan.
	Debt cost expense and interest expense related to the stock warrants and availability fee and accrued interest on outstanding borrowings, respectively, for the three and six months ended September 30, 2013 and 2012 was recorded in our condensed consolidated statement of operations as follows:
		Three Months Ended				Six Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Debt cost expense	$	-	$	128	$	-	$	272
	Interest expense		42		233		81		422
	At September 30, 2013, we had $150 thousand in accrued interest under the Replacement Note, which is included in accrued expenses on our condensed consolidated balance sheet, and no accrued interest under the 2013 Note.
	Letter Agreement
	Pursuant to the Letter Agreement, Mr. Pell has agreed to provide financial assistance to us in the amount of up to $5.0 million, if necessary to support our operations, for a period ending on the earlier of (i) July 1, 2014 or (ii) our raising debt or equity capital in the amount of $5.0 million or more. This financial assistance, if drawn by us, would be in the form of an additional loan, share purchase, or financing transaction, on such terms as we and Mr. Pell may determine. As of September 30, 2013, we had not utilized the financial assistance agreement.

Note_6_Common_Stock

Note 6. Common Stock	6 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Note 6. Common Stock
	On April 27, 2012, we entered into a purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“LPC”), pursuant to which we have the right to sell to LPC up to $15.0 million in shares of our common stock from time-to-time over a period of up to three years, subject to certain limitations and conditions set forth in the Purchase Agreement. This total maximum amount of $15.0 million would increase to $21.0 million if the aggregate market value of shares of our common stock held by non-affiliates reached at least $75.0 million during the three-year term of the Purchase Agreement. The Purchase Agreement contains customary representations, warranties and agreements between us and LPC, limitations (market price of our common stock and LPC’s ownership limit) and conditions to completing future sale transactions, indemnification rights and other obligations of the parties. In connection with the initial purchase under the Purchase Agreement, and any future sales under the Purchase Agreement, Mr. Pell waived the repayment requirement under the Original Agreement. On July 26, 2012, we amended the Purchase Agreement with LPC to, among other things, create a threshold price of $3.00 for the sale of our common stock to LPC, as calculated pursuant to the formula provided in the Purchase Agreement.
	As consideration for LPC entering into the Purchase Agreement and for its initial purchase of $1.0 million of our common stock in April 2012, we issued to LPC 175,333 shares of our common stock. As consideration for LPC’s remaining future purchases under the Purchase Agreement, we also will issue to LPC, on a pro rata basis in connection with each purchase of shares by LPC, up to a total of approximately 215,000 additional shares of our common stock. We did not receive any cash proceeds from the issuance of 175,333 shares and will not receive any proceeds upon the issuance of any of the remaining 215,000 shares.
	The following table summarizes the common stock issued and cash received in connection with the Purchase Agreement:
	Month	Description	Number of		Share		Gross
			Shares of		Price		Proceeds
			Common Stock
			Issued
	Apr-12	Initial purchase shares		599,880	$	1.667	$	1,000
	Apr-12	Initial commitment shares		160,000		-		-
	Apr-12	Initial additional commitment shares (1)		15,333		-		-
				775,213			$	1,000
	(1) Calculated as follows: ($1.0 million stock purchase divided by $15.0 million total maximum amount) multiplied by 230,000 additional commitment shares.
	In connection with the Purchase Agreement, we incurred $122 thousand of costs associated with investment banking fees, legal fees, and expense reimbursement to LPC. Our net proceeds from the sale of the initial purchase shares were $878 thousand.

Note_7_StockBased_Awards

Note 7. Stock-Based Awards	6 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 7. Stock-Based Awards
	We maintain the following stockholder-approved equity incentive plans:
		●	The 2000 Stock Incentive Plan (the “2000 Plan”) authorized the issuance of up to 4,500,000 shares of common stock covering several different types of awards, including stock options, restricted shares, stock appreciation rights, and performance shares.
		●	The 2007 Stock Incentive Plan (the “2007 Plan”) authorized the issuance of up to 5,000,000 shares of common stock covering several different types of awards, including stock options, restricted shares, stock appreciation rights, and other stock-based awards. On July 26, 2012, our stockholders approved an amendment to the 2007 Plan further increasing the number of authorized shares issuable under the plan to 7,000,000 shares of common stock.
		●	The 2003 Director Option Plan (the “2003 Plan”) authorized the issuance of up to 450,000 shares of common stock covering the annual automatic grant, unless waived, of 10,000 stock options per outside director per year. The 2003 Plan also provides for granting newly elected or appointed outside directors a one-time grant of 10,000 stock options.
	The stock option plans provide that options may be granted at an exercise price of 100% of fair market value of our common stock on the date of grant, may be exercised in full or in installments, at the discretion of our Board of Directors (the “Board”) or its Compensation Committee (the “Compensation Committee”), and must be exercised within ten years from date of grant. We recognize stock-based compensation expense on a straight-line basis over the requisite service period based on fair values, generally four years. We use historical data to estimate expected employee behaviors related to option exercises and forfeitures and included these expected forfeitures as a part of the estimate of stock-based compensation expense as of the grant date.
	Stock Options
	The following table summarizes stock options activity for the six months ended September 30, 2013:
			Number			Exercise									Weighted		Weighted
			of Shares			Price Range									Average		Average
															Exercise Price		Remaining
																	Contractual Life
	Outstanding at March 31, 2013			5,780,608		$	0.79		–			$	4.88		$	2.09		6.6
	Granted			721,000		$	0.9		–			$	1.09			1.03
	Exercised			-						-						-
	Canceled (1)			(1,994,833	)	$	0.97		–			$	3.62			2.24
	Outstanding at September 30, 2013			4,506,775		$	0.85		–			$	4.88		$	1.85		6.1
	Vested and expected to vest at September 30, 2013			4,439,571		$	0.85		–			$	4.88		$	1.85		6.1
	Exercisable at September 30, 2013			3,466,004		$	0.85		–			$	4.88		$	1.96		5.3
	(1) Includes cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari (1,125,000 stock options), and our former VP, Corporate Development and Chief Financial Officer, Katherine L. Wolf (612,458 stock options).
	The weighted average fair value of options granted during the three months ended September 30, 2013 and 2012 was $0.61 and $0.91 per share, respectively. The weighted average fair value of options granted during the six months ended September 30, 2013 and 2012 was $0.68 and $0.93 per share, respectively.
	The total intrinsic value (the excess of the market price over the exercise price) was approximately $10 thousand for stock options outstanding, $8 thousand for stock options exercisable, and $10 thousand for stock options vested and expected to vest as of September 30, 2013. The total intrinsic value for stock options exercised during the three and six months ended September 30, 2012 was approximately $21 thousand and $23 thousand, respectively. There were no stock options exercised during the three and six months ended September 30, 2013.
	We do not expect to realize any tax benefits from future disqualifying dispositions, if any, because we currently have a full valuation allowance against our deferred tax assets.
	Restricted Stock
	The following table summarizes restricted stock activity for the six months ended September 30, 2013:
			Number			Weighted
			of Shares			Average
						Grant Price
	Nonvested at March 31, 2013			122,044		$	2.37
	Granted			165,000			0.95
	Vested			(79,142	)		2.16
	Forfeited			-			-
	Nonvested at September 30, 2013			207,902		$	1.32
	We grant restricted stock awards (“RSA’s”) to our executive officers and management employees (collectively “management”) and members of our Board from time-to-time. There is no direct costs to the recipients of the RSA’s, except for any applicable taxes upon lapsing of the restrictions. In fiscal 2011, the Compensation Committee adopted a performance incentive plan (“PIP”) that provides for the payment of bonuses to management based on the attainment of specified Company performance and individual objectives. Any payments that may be due under the PIP will be paid in shares of restricted stock awarded under our 2007 Plan. The nonvested balance of 207,902 shares represent RSAs awarded to management under the fiscal 2012 PIP and to Board members for the annual grant at our fiscal 2013 annual stockholders meeting. The Compensation Committee did not approve a PIP for fiscal 2013.
	Stock-Based Compensation Expense
	We account for stock-based awards issued to employees in accordance with the provisions of ASC 718 (Topic 718, Compensation – Stock Compensation). We recognize stock-based compensation expense on a straight-line uniform basis over the service period of the award, which is generally four years for employees. Stock-based awards issued to consultants are accounted for in accordance with the provisions of ASC 718 and ASC 505-50 (Subtopic 50 “Equity-Based Payments to Non-Employees” of Topic 505, Equity). Options granted to consultants are periodically revalued as the options vest, and are recognized as an expense over the related period of service or the vesting period, whichever is longer. Under the provisions of ASC 718, members of the Board are considered employees for calculation of stock-based compensation expense.
	We estimated the fair value of the stock options granted on the date of grant using a Black-Scholes valuation model that used the weighted average assumptions noted in the following table. The risk-free interest rate assumption we use is based upon United States Treasury interest rates appropriate for the expected life of the awards. The expected life (estimated period of time that we expect employees, consultants and directors to hold their stock options) was estimated based on historical rates for two group classifications, (i) employees and consultants and (ii) outside directors. Expected volatility was based on historical volatility of our stock price for a period equal to the stock option’s expected life and calculated on a daily basis. The expected dividend rate is zero since we do not currently pay cash dividends on our common stock and do not anticipate doing so in the foreseeable future.
			Three Months Ended						Six Months Ended
			September 30,						September 30,
			2013			2012			2013			2012
	Risk-free interest rate			1.38	%		1.02	%		1.16	%		1.03	%
	Expected life (in years)			5.1			6.4			5.5			6.4
	Expected volatility			75	%		85	%		80	%		84	%
	Expected dividend yield			--			--			--			--
	We determine stock-based compensation expense for performance based restricted stock based upon the fair value of our common stock at the date of grant and recognize expense based upon the most probable outcome as to whether the performance targets will be achieved and the stock-based compensation being earned.
	Stock-based compensation expense for the three and six months ended September 30, 2013 and 2012 was recorded in our condensed consolidated statement of operations as follows:
			Three Months Ended						Six Months Ended
			September 30,						September 30,
			2013			2012			2013			2012
	Cost of sales		$	12		$	22		$	42		$	69
	Selling, general, and administrative expenses (1)			(244	)		538			265			907
	Research and development expenses			5			9			21			36
	Total stock-based compensation expense		$	(227	)	$	569		$	328		$	1,012
	(1) Reflects reversal of stock-based compensation expense of $289 thousand for the cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari.
	At September 30, 2013, unrecognized stock-based compensation expense related to stock options was approximately $0.8 million and is expected to be recognized over a weighted average period of approximately 2.7 years. At September 30, 2012, unrecognized stock-based compensation expense related to nonvested (restricted stock) awards was approximately $0.2 million, which is expected to be recognized over a weighted average period of approximately 1.1 years.

Note_8_Treasury_Stock

Note 8. Treasury Stock	6 Months Ended
	Sep. 30, 2013
Disclosure Text Block Supplement [Abstract]	'
Treasury Stock [Text Block]	'
	Note 8. Treasury Stock
	The following table summarizes treasury stock activity for the three and six months ended September 30, 2013 and 2012:
	Three Months Ended	Number		Cost		Weighted
		of Shares				Average
		Repurchased				Purchase Price
	30-Sep-13		10,054	$	10	$	1.06
	30-Sep-12		17,417	$	24	$	1.36
	Six Months Ended
	30-Sep-13		25,525	$	28	$	1.11
	30-Sep-12		17,417	$	24	$	1.36
	The shares were purchased from management to cover income tax withholdings upon the lapse of restrictions on their restricted stock awards. Although not required to under our equity incentive plans, we anticipate repurchasing shares in a similar arrangement in the future.

Note_9_Segment_Information

Note 9. Segment Information	6 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	Note 9. Segment Information
	We have two reportable segments, medical and industrial. Each of these operating segments has unique characteristics. Management evaluates the revenue and profitability performance of each of our product lines to make operating and strategic decisions. We have no intersegment revenue.
	Our medical segment designs, develops, manufactures, and markets our advanced line of endoscopy-based products, including our state-of-the-art flexible endoscopes, and our EndoSheath technology (referred to as a sheath or EndoSheath disposable) for a variety of specialties and markets.
	Our industrial segment, through our wholly-owned subsidiary Machida, designs, manufactures, and sells borescopes to a variety of users, primarily in the aircraft engine manufacturing and aircraft engine maintenance industries. A borescope is an instrument that uses optical fibers for the visual inspection of narrow cavities. Our borescopes are used to inspect aircraft engines, casting parts and ground turbines, among other items.
	The following table presents key financial highlights, by reportable segments:
	Three Months Ended	Medical			Industrial			Adjustments *			Consolidated
	30-Sep-13
	Net sales	$	3,399		$	569		$	-		$	3,968
	Gross profit		981			214			-			1,195
	Operating (loss) income		(1,345	)		62			-			(1,283	)
	Interest expense, net		(43	)		-			-			(43	)
	Depreciation and amortization		170			3			-			173
	Stock-based compensation expense(1)		(221	)		(6	)		-			(227	)
	Total assets		11,240			1,333			(1,840	)		10,733
	Expenditures for fixed assets		46			-			-			46
	30-Sep-12
	Net sales	$	2,724		$	1,015		$	-		$	3,739
	Gross profit		746			324			-			1,070
	Operating (loss) income		(2,688	)		67			-			(2,621	)
	Interest expense, net		(236	)		-			-			(236	)
	Depreciation and amortization		196			6			-			202
	Stock-based compensation expense		560			9			-			569
	Total assets		12,751			1,753			(1,974	)		12,530
	Expenditures for fixed assets		19			-			-			19
	Six Months Ended
	30-Sep-13
	Net sales	$	6,428		$	1,192		$	-		$	7,620
	Gross profit		1,774			501			-			2,275
	Operating (loss) income		(3,732	)		60			-			(3,672	)
	Interest expense, net		(84	)		-			-			(84	)
	Depreciation and amortization		355			7			-			362
	Stock-based compensation expense(1)		309			19			-			328
	Expenditures for fixed assets		46			-			-			46
	30-Sep-12
	Net sales	$	5,220		$	1,915		$	-		$	7,135
	Gross profit		1,341			642			-			1,983
	Operating (loss) income		(5,032	)		107			-			(4,925	)
	Interest expense, net		(429	)		-			-			(429	)
	Depreciation and amortization		393			13			-			406
	Stock-based compensation expense		960			52			-			1,012
	Expenditures for fixed assets		55			-			-			55
		September 30,
	* Adjustments	2013			2012
	Intercompany eliminations	$	(1,154	)	$	(1,288	)
	Investment in subsidiaries		(686	)		(686	)
	Total adjustments	$	(1,840	)	$	(1,974	)
	(1) Reflects reversal of stock-based compensation expense of $289 thousand for the cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari.
	The following table presents the reconciliation to loss before provision for income taxes for the three and six months ended September 30, 2013 and 2012.
		Three Months Ended						Six Months Ended
		September 30,						September 30,
	Reconciliation to loss before provision for income taxes:	2013			2012			2013			2012
	Operating loss	$	(1,283	)	$	(2,621	)	$	(3,672	)	$	(4,925	)
	Interest expense, net		(43	)		(236	)		(84	)		(429	)
	Other, net		6			(35	)		2			(40	)
	Debt cost expense		-			(128	)		-			(272	)
	Loss on extinguishment of debt		-			(1,244	)		-			(1,244	)
	Loss before provision for income taxes	$	(1,320	)	$	(4,264	)	$	(3,754	)	$	(6,910	)

Note_10_Subsequent_Event

Note 10. Subsequent Event	6 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Note 10. Subsequent Event
	On October 7, 2013, we borrowed $1.0 million of the $3.5 million commitment under the 2013 Note. At the time of the borrowing, the 2013 Note conversion price of $0.89 was below the closing bid price of our common stock of $0.95, which resulted in a beneficial conversion feature. The beneficial conversion feature is calculated at its intrinsic value (that is, the difference between the conversion price and the fair value of the common stock into which the debt is convertible, multiplied by the number of shares into which the debt is convertible) at the date of borrowing.
	The beneficial conversion feature of the $1.0 million borrowing on October 7, 2013 amounted to $67 thousand, which will be recorded as a convertible debt discount with a corresponding increase to additional paid-in capital. The amount will be amortized over a five-year period from the borrowing date to the Maturity Date.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	6 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Business Description and Basis of Presentation [Text Block]	'
	Basis of Presentation and Preparation
	We have prepared the condensed consolidated financial statements included herein according to generally accepted accounting principles in the United States of America (“U.S. GAAP”), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and include, in the opinion of management, all adjustments that we consider necessary for a fair presentation of such information. We have condensed or omitted certain information and footnote disclosures normally included in financial statements pursuant to those rules and regulations. We believe, however, that our disclosures are adequate to make the information presented not misleading.
	The results for the interim periods presented are not necessarily indicative of results to be expected for the full fiscal year. Please read these condensed consolidated financial statements in conjunction with the consolidated financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2013.
Liquidity Disclosure [Policy Text Block]	'
	Liquidity and Capital Resources
	We have incurred substantial operating losses since our inception and there can be no assurance that we will ever achieve or sustain a profitable level of operations in the future. We anticipate negative cash flows from operations during the remainder of fiscal 2014, driven by continued investment in a direct sales force for the U.S. market, spending for marketing, spending for research and development, and general business operations. As of September 30, 2013, we had cash and cash equivalents totaling approximately $0.5 million. We expect that our cash at September 30, 2013, together with the $3.5 million of capital available as of September 30, 2013 under a revolving convertible promissory note dated September 25, 2013 (the “2013 Note”) and up to $5.0 million of capital to be made available to us, subject to certain conditions and an expiration date of July 1, 2014, under a letter agreement dated June 21, 2013 with Lewis C. Pell, our Chairman (the “Letter Agreement”) (see Note 5. Convertible Debt – Related Party for additional information), should be sufficient to fund our operations through at least September 30, 2014. However, if our performance expectations fall short (including our failure to generate expected levels of sales) or our expenses exceed expectations, or if the commitments under the 2013 Note or the Letter Agreement become unavailable, we will need to secure additional financing and/or reduce our expenses to continue our operations. Our failure to do so would have a material adverse impact on our prospects and financial condition. There can be no assurance that any contemplated additional financing will be available on terms acceptable to us, if at all. If required, we believe we would be able to reduce our expenses to a sufficient level to continue to operate as a going concern.
Basis of Accounting, Policy [Policy Text Block]	'
	Summary of Significant Accounting Policies
	Our condensed consolidated financial statements are prepared in accordance with U.S. GAAP. These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable, based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. To the extent there are any differences (other than nominal differences) between these estimates, judgments or assumptions and actual results, our financial statements will be affected.
	The accounting policies that reflect our more significant estimates, judgments, and assumptions and that we believe are the most critical to aid in fully understanding and evaluating our reported financial results include the following:
	• Revenue recognition;
	• Stock-based compensation expense;
	• Allowances for doubtful accounts;
	• Inventory obsolescence and realization;
	• Fair value measurements of convertible debt – related party;
	• Obligations under warranties; and
	• Other contingencies.
	The accompanying condensed consolidated financial statements reflect the accounts of the Company. All significant inter-company accounts and transactions have been eliminated in consolidation.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value Measurements
	The carrying amounts reflected in our condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued expenses, accrued compensation, and capital lease obligations approximate fair value due to their short-term nature. The fair value of our convertible debt – related party is based on its face value, which is equal to its carrying value.
	In determining the fair value of the convertible debt – related party, we analyzed its attributes (coupon rate, conversion price, and the percentage of market cap the face value of the debt instrument was prior to the announcement of the debt) to public company convertible debt issuances from June 2011 through September 2012 (a sixteen (16) month period) in the healthcare industry. We determined the convertible debt was not issued at a discount as its fair value was equal to its face (carrying) value.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Concentration of Credit Risk
	Concentration of credit risk with respect to accounts receivable relates to certain domestic and international customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, when appropriate, we obtain advance payments for our international sales. As a consequence, we believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses, but historically we have not experienced any significant credit losses related to any individual customer or group of customers in any particular industry or geographic area.
	The following table summarizes net sales to our significant customers, which accounted for more than 10% of total segment net sales and total accounts receivable, net:

Note_1_Summary_of_Significant_1

Note 1. Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]	'
		Three Months Ended						Six Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Medical segment
	Stryker	$	1,201		$	395		$	2,346		$	1,008
	Percentage of total segment net sales		35	%		15	%		36	%		19	%
	Percentage of total net sales		30	%		11	%		31	%		14	%
	Percentage of total accounts receivable, net		36	%		11	%
	Industrial segment
	Pratt & Whitney, a division of United Technology Corporation	$	31		$	426		$	66		$	706
	Percentage of total segment net sales		5	%		42	%		6	%		37	%
	Percentage of total net sales		1	%		11	%		1	%		10	%
	Percentage of accounts receivable, net		1	%		16	%

Note_2_Basic_and_Diluted_Net_L1

Note 2. Basic and Diluted Net Loss per Common Share (Tables)	6 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
		September 30,
		2013		2012
	Convertible debt		16,666,666		12,500,000
	Stock options		4,506,775		6,291,179
	Warrants		1,880,620		1,880,620
	Restricted stock		207,902		177,150
	Total anti-dilutive securities		23,261,963		20,848,949

Note_3_Inventories_Tables

Note 3. Inventories (Tables)	6 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
		September 30,		March 31,
		2013		2013
	Raw materials	$	4,465	$	4,352
	Work in process		602		427
	Finished goods		616		379
	Inventories, net	$	5,683	$	5,158

Note_5_Convetible_Debt_Related1

Note 5. Convetible Debt - Related Party (Tables)	6 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	'
		Three Months Ended				Six Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Debt cost expense	$	-	$	128	$	-	$	272
	Interest expense		42		233		81		422

Note_6_Common_Stock_Tables

Note 6. Common Stock (Tables)	6 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Common Stock Issued and Cash Received in Purchase Agreement	'
	Month	Description	Number of		Share		Gross
			Shares of		Price		Proceeds
			Common Stock
			Issued
	Apr-12	Initial purchase shares		599,880	$	1.667	$	1,000
	Apr-12	Initial commitment shares		160,000		-		-
	Apr-12	Initial additional commitment shares (1)		15,333		-		-
				775,213			$	1,000

Note_7_StockBased_Awards_Table

Note 7. Stock-Based Awards (Tables)	6 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
		Number			Exercise									Weighted		Weighted
		of Shares			Price Range									Average		Average
														Exercise Price		Remaining
																Contractual Life
	Outstanding at March 31, 2013		5,780,608		$	0.79		–			$	4.88		$	2.09		6.6
	Granted		721,000		$	0.9		–			$	1.09			1.03
	Exercised		-						-						-
	Canceled (1)		(1,994,833	)	$	0.97		–			$	3.62			2.24
	Outstanding at September 30, 2013		4,506,775		$	0.85		–			$	4.88		$	1.85		6.1
	Vested and expected to vest at September 30, 2013		4,439,571		$	0.85		–			$	4.88		$	1.85		6.1
	Exercisable at September 30, 2013		3,466,004		$	0.85		–			$	4.88		$	1.96		5.3
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	'
		Number			Weighted
		of Shares			Average
					Grant Price
	Nonvested at March 31, 2013		122,044		$	2.37
	Granted		165,000			0.95
	Vested		(79,142	)		2.16
	Forfeited		-			-
	Nonvested at September 30, 2013		207,902		$	1.32
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
		Three Months Ended						Six Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Risk-free interest rate		1.38	%		1.02	%		1.16	%		1.03	%
	Expected life (in years)		5.1			6.4			5.5			6.4
	Expected volatility		75	%		85	%		80	%		84	%
	Expected dividend yield		--			--			--			--
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
		Three Months Ended						Six Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Cost of sales	$	12		$	22		$	42		$	69
	Selling, general, and administrative expenses (1)		(244	)		538			265			907
	Research and development expenses		5			9			21			36
	Total stock-based compensation expense	$	(227	)	$	569		$	328		$	1,012

Note_8_Treasury_Stock_Tables

Note 8. Treasury Stock (Tables)	6 Months Ended
	Sep. 30, 2013
Disclosure Text Block Supplement [Abstract]	'
Class of Treasury Stock [Table Text Block]	'
	Three Months Ended	Number		Cost		Weighted
		of Shares				Average
		Repurchased				Purchase Price
	30-Sep-13		10,054	$	10	$	1.06
	30-Sep-12		17,417	$	24	$	1.36
	Six Months Ended
	30-Sep-13		25,525	$	28	$	1.11
	30-Sep-12		17,417	$	24	$	1.36

Note_9_Segment_Information_Tab

Note 9. Segment Information (Tables)	6 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	Three Months Ended	Medical			Industrial			Adjustments *			Consolidated
	30-Sep-13
	Net sales	$	3,399		$	569		$	-		$	3,968
	Gross profit		981			214			-			1,195
	Operating (loss) income		(1,345	)		62			-			(1,283	)
	Interest expense, net		(43	)		-			-			(43	)
	Depreciation and amortization		170			3			-			173
	Stock-based compensation expense(1)		(221	)		(6	)		-			(227	)
	Total assets		11,240			1,333			(1,840	)		10,733
	Expenditures for fixed assets		46			-			-			46
	30-Sep-12
	Net sales	$	2,724		$	1,015		$	-		$	3,739
	Gross profit		746			324			-			1,070
	Operating (loss) income		(2,688	)		67			-			(2,621	)
	Interest expense, net		(236	)		-			-			(236	)
	Depreciation and amortization		196			6			-			202
	Stock-based compensation expense		560			9			-			569
	Total assets		12,751			1,753			(1,974	)		12,530
	Expenditures for fixed assets		19			-			-			19
	Six Months Ended
	30-Sep-13
	Net sales	$	6,428		$	1,192		$	-		$	7,620
	Gross profit		1,774			501			-			2,275
	Operating (loss) income		(3,732	)		60			-			(3,672	)
	Interest expense, net		(84	)		-			-			(84	)
	Depreciation and amortization		355			7			-			362
	Stock-based compensation expense(1)		309			19			-			328
	Expenditures for fixed assets		46			-			-			46
	30-Sep-12
	Net sales	$	5,220		$	1,915		$	-		$	7,135
	Gross profit		1,341			642			-			1,983
	Operating (loss) income		(5,032	)		107			-			(4,925	)
	Interest expense, net		(429	)		-			-			(429	)
	Depreciation and amortization		393			13			-			406
	Stock-based compensation expense		960			52			-			1,012
	Expenditures for fixed assets		55			-			-			55
Segment Reporting, Measurement Differences Between Segment and Consolidated Profit (Loss)	'
		September 30,
	* Adjustments	2013			2012
	Intercompany eliminations	$	(1,154	)	$	(1,288	)
	Investment in subsidiaries		(686	)		(686	)
	Total adjustments	$	(1,840	)	$	(1,974	)
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	'
		Three Months Ended						Six Months Ended
		September 30,						September 30,
	Reconciliation to loss before provision for income taxes:	2013			2012			2013			2012
	Operating loss	$	(1,283	)	$	(2,621	)	$	(3,672	)	$	(4,925	)
	Interest expense, net		(43	)		(236	)		(84	)		(429	)
	Other, net		6			(35	)		2			(40	)
	Debt cost expense		-			(128	)		-			(272	)
	Loss on extinguishment of debt		-			(1,244	)		-			(1,244	)
	Loss before provision for income taxes	$	(1,320	)	$	(4,264	)	$	(3,754	)	$	(6,910	)

Note_1_Summary_of_Significant_2

Note 1. Summary of Significant Accounting Policies (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013	Sep. 30, 2012	Mar. 31, 2012
Note 1. Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
Cash and Cash Equivalents, at Carrying Value (in Dollars)	$455,000	$788,000	$3,063,000	$2,674,000
Chairman, Lewis C. Pell [Member]	'	'	'	'
Note 1. Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
Long Term Debt Maximum Amount Lender Agreed To Provide Financial Assistance (in Dollars)	5,000,000	'	'	'
Stryker [Member] | Sales Revenue, Goods, Net [Member]	'	'	'	'
Note 1. Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
Percentage of Total Segment Net Sales and Total Accounts Receivable, Net	10.00%	'	'	'
Convertible Debt [Member]	'	'	'	'
Note 1. Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
Line of Credit Facility, Maximum Borrowing Capacity (in Dollars)	$3,500,000	'	'	'

Note_1_Summary_of_Significant_3

Note 1. Summary of Significant Accounting Policies (Details) - Significant Customers (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Medical segment	'	'	'	'
Segment Net Sales (in Dollars)	$3,968	$3,739	$7,620	$7,135
Stryker [Member] | Medical [Member]	'	'	'	'
Medical segment	'	'	'	'
Segment Net Sales (in Dollars)	1,201	395	2,346	1,008
Percentage of total segment net sales	35.00%	15.00%	36.00%	19.00%
Percentage of total net sales	30.00%	11.00%	31.00%	14.00%
Percentage of accounts receivable, net	36.00%	11.00%	'	'
Pratt & Whitney [Member] | Industrial [Member]	'	'	'	'
Medical segment	'	'	'	'
Segment Net Sales (in Dollars)	31	426	66	706
Percentage of total segment net sales	5.00%	42.00%	6.00%	37.00%
Percentage of total net sales	1.00%	11.00%	1.00%	10.00%
Percentage of accounts receivable, net	1.00%	16.00%	'	'
Medical [Member]	'	'	'	'
Medical segment	'	'	'	'
Segment Net Sales (in Dollars)	3,399	2,724	6,428	5,220
Industrial [Member]	'	'	'	'
Medical segment	'	'	'	'
Segment Net Sales (in Dollars)	$569	$1,015	$1,192	$1,915

Note_2_Basic_and_Diluted_Net_L2

Note 2. Basic and Diluted Net Loss per Common Share (Details) - Equity Securities Excluded From The Calculation of Fully Diluted Loss Per Share	6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-Dilutive Securities	23,261,963	20,848,949
Convertible Debt Securities [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-Dilutive Securities	16,666,666	12,500,000
Equity Option [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-Dilutive Securities	4,506,775	6,291,179
Warrant [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-Dilutive Securities	1,880,620	1,880,620
Restricted Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-Dilutive Securities	207,902	177,150

Note_3_Inventories_Details_Inv

Note 3. Inventories (Details) - Inventories (USD $)	Sep. 30, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
Inventories [Abstract]	'	'
Raw materials	$4,465	$4,352
Work in process	602	427
Finished goods	616	379
Inventories, net	$5,683	$5,158

Note_5_Convetible_Debt_Related2

Note 5. Convetible Debt - Related Party (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 19, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
			The 2013 Note [Member]	Replacement Note [Member]	Replacement Note [Member]	Replacement Note [Member]	The Original Agreement [Member]	The Original Agreement [Member]	The Letter Agreement [Member]
				Chairman, Lewis C. Pell [Member]			Chairman, Lewis C. Pell [Member]
Note 5. Convetible Debt - Related Party (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Related Party Transaction, Rate	'	'	1.66%	'	0.84%	'	'	'	'
Debt Instrument, Convertible, Conversion Price (in Dollars per share)	'	'	$0.89	'	$1.20	'	'	'	'
Convertible Debt, Noncurrent	$20,000,000	$17,000,000	'	$15,000,000	'	$20,000,000	'	'	'
Notes Payable, Related Parties, Additional Borrowings Increase (Decrease)	'	'	'	'	5,000,000	'	'	'	'
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)	'	'	'	'	'	'	1,880,620	'	'
Fair Value Assumptions, Exercise Price (in Dollars per share)	'	'	'	'	'	'	'	$1.86	'
Deferred Costs, Noncurrent	'	'	'	'	'	1,200,000	'	'	'
Accrued Liabilities, Current	778,000	728,000	'	'	150,000	'	'	'	'
Long Term Debt Maximum Amount Lender Agreed To Provide Financial Assistance	'	'	'	'	'	'	'	'	$5,000,000

Note_5_Convetible_Debt_Related3

Note 5. Convetible Debt - Related Party (Details) - Debt Cost Expense and Interest Expense Related to Outstanding Borrowings (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Note 5. Convetible Debt - Related Party (Details) - Debt Cost Expense and Interest Expense Related to Outstanding Borrowings [Line Items]	'	'	'	'
Debt cost expense	'	$128	'	$272
Interest expense	44	237	85	431
Related Party [Member]	'	'	'	'
Note 5. Convetible Debt - Related Party (Details) - Debt Cost Expense and Interest Expense Related to Outstanding Borrowings [Line Items]	'	'	'	'
Interest expense	$42	$233	$81	$422

Note_6_Common_Stock_Details

Note 6. Common Stock (Details) (USD $)	1 Months Ended		3 Months Ended	6 Months Ended		25 Months Ended
	Apr. 27, 2012	Apr. 30, 2012	Jun. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Apr. 27, 2014	Jul. 26, 2012
Note 6. Common Stock (Details) [Line Items]	'	'	'	'	'	'	'
Maximum Amount Common Stock Available to Sell in Purchase Agreement	$15,000,000	'	'	'	'	$21,000,000	'
Common Stock, Other Value, Outstanding	'	'	'	'	'	75,000,000	'
Fair Value Assumptions, Expected Term	'	'	'	'	'	'3 years	'
Sale of Stock, Price Per Share (in Dollars per share)	'	'	'	'	'	'	$3
Proceeds from Sale of Treasury Stock	1,000,000	1,000,000	'	'	'	'	'
Stock Issued During Period, Shares, New Issues (in Shares)	'	'	'	'	'	175,333	'
Stock Issued During Period, Shares, Conversion of Convertible Securities (in Shares)	'	'	'	230,000	'	'	'
Debt Issuance Cost	122,000	'	'	'	'	'	'
Proceeds from Issuance of Common Stock	'	'	878,000	'	878,000	'	'
Commitment Shares [Member]	'	'	'	'	'	'	'
Note 6. Common Stock (Details) [Line Items]	'	'	'	'	'	'	'
Stock Issued During Period, Value, Conversion of Convertible Securities	'	'	'	1,000,000	'	'	'
Lincoln Park Capital Fund, LLC [Member]	'	'	'	'	'	'	'
Note 6. Common Stock (Details) [Line Items]	'	'	'	'	'	'	'
Stock Issued During Period, Shares, New Issues (in Shares)	'	'	'	'	'	175,333	'
Maximum [Member]	'	'	'	'	'	'	'
Note 6. Common Stock (Details) [Line Items]	'	'	'	'	'	'	'
Stock Issued During Period, Shares, New Issues (in Shares)	'	'	'	'	'	215,000	'
Stock Issued During Period, Value, Conversion of Convertible Securities	'	'	'	15,000,000	'	'	'

Note_6_Common_Stock_Details_Su

Note 6. Common Stock (Details) - Summary Common Stock Issued and Cash Received (USD $)	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Apr. 27, 2012	Apr. 30, 2012		Sep. 30, 2013	Mar. 31, 2013
Note 6. Common Stock (Details) - Summary Common Stock Issued and Cash Received [Line Items]	'	'		'	'
Number of Shares of Common Stock Issued	'	775,213		46,414,000	46,249,000
Share Price (in Dollars per share)	'	'		$0.01	$0.01
Gross Proceeds (in Dollars)	$1,000	$1,000		'	'
Initial Purchase Shares [Member]	'	'		'	'
Note 6. Common Stock (Details) - Summary Common Stock Issued and Cash Received [Line Items]	'	'		'	'
Number of Shares of Common Stock Issued	'	599,880		'	'
Share Price (in Dollars per share)	'	$1.67		'	'
Gross Proceeds (in Dollars)	'	1,000		'	'
Initial Commitment Shares [Member]	'	'		'	'
Note 6. Common Stock (Details) - Summary Common Stock Issued and Cash Received [Line Items]	'	'		'	'
Number of Shares of Common Stock Issued	'	160,000		'	'
Initial Additional Commitment Shares [Member]	'	'		'	'
Note 6. Common Stock (Details) - Summary Common Stock Issued and Cash Received [Line Items]	'	'		'	'
Number of Shares of Common Stock Issued	'	15,333	[1]	'	'
Share Price (in Dollars per share)	'	'	[1]	'	'
Gross Proceeds (in Dollars)	'	'	[1]	'	'
[1]	Calculated as follows: ($1.0 million stock purchase divided by $15.0 million total maximum amount) multiplied by 230,000 additional commitment shares.

Note_7_StockBased_Awards_Detai

Note 7. Stock-Based Awards (Details) (USD $)

0 Months Ended

3 Months Ended

6 Months Ended

28 Months Ended

30 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

Aug. 15, 2003

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2014

Dec. 31, 2014

Jul. 26, 2012

Aug. 15, 2007

Aug. 15, 2000

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Restricted Stock [Member]

Restricted Stock [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

Cynthia F. Ansari [Member]

Katherine L. Wolf [Member]

Cynthia F. Ansari [Member]

Cynthia F. Ansari [Member]

Note 7. Stock-Based Awards (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

450,000

'

'

'

'

'

'

7,000,000

5,000,000

4,500,000

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,125,000

612,458

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)

'

$0.61

$0.91

$0.68

$0.93

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value (in Dollars)

'

$10,000

'

$10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value (in Dollars)

'

8,000

'

8,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value (in Dollars)

'

10,000

'

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value (in Dollars)

'

'

21,000

'

23,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number

'

'

'

'

'

'

'

'

'

'

207,902

122,044

'

'

'

'

'

'

'

'

Share-based Compensation (in Dollars)

'

-227,000

[1]

569,000

328,000

[1]

1,012,000

'

'

'

'

'

'

'

289,000

289,000

-244,000

[1]

538,000

[1]

265,000

[1]

907,000

[1]

'

'

Unrecognized Stock Based Compensation Expense Related To Options (in Dollars)

'

800,000

'

800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

'

'

'

'

'

'1 year 36 days

'2 years 255 days

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)

'

'

$200,000

'

$200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

Reflects reversal of stock-based compensation expense of $289 thousand for the cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari.

Note_7_StockBased_Awards_Detai1

Note 7. Stock-Based Awards (Details) - Stock Options Activity (USD $)	0 Months Ended	1 Months Ended	6 Months Ended
	Aug. 15, 2003	Mar. 31, 2013	Sep. 30, 2013
Note 7. Stock-Based Awards (Details) - Stock Options Activity [Line Items]	'	'	'
Outstanding - Number of Shares (in Shares)	'	5,780,608	4,506,775
Oustanding - Exercise Price Range Minimum	'	$0.79	$0.85
Oustanding - Exercise Price Range Maximum	'	$4.88	$4.88
Outstanding - Weighted Average Exercise Price	'	$2.09	$1.85
Outstanding - Weighted Average Remaining Contractual Life	'	'6 years 219 days	'6 years 36 days
Granted (in Shares)	10,000	'	'
Granted	'	$0.79	$0.85
Granted	'	$4.88	$4.88
Vested and expected to vest at September 30, 2013	'	$0.79	$0.85
Vested and expected to vest at September 30, 2013	'	$4.88	$4.88
Exercisable at September 30, 2013	'	$0.79	$0.85
Exercisable at September 30, 2013	'	$4.88	$4.88
Granted [Member]	'	'	'
Note 7. Stock-Based Awards (Details) - Stock Options Activity [Line Items]	'	'	'
Oustanding - Exercise Price Range Minimum	'	'	$0.90
Oustanding - Exercise Price Range Maximum	'	'	$1.09
Granted (in Shares)	'	'	721,000
Granted	'	'	$0.90
Granted	'	'	$1.09
Granted	'	'	$1.03
Vested and expected to vest at September 30, 2013	'	'	$0.90
Vested and expected to vest at September 30, 2013	'	'	$1.09
Exercisable at September 30, 2013	'	'	$0.90
Exercisable at September 30, 2013	'	'	$1.09
Exercised [Member]	'	'	'
Note 7. Stock-Based Awards (Details) - Stock Options Activity [Line Items]	'	'	'
Exercised (in Shares)	'	'	0
Canceled [Member]	'	'	'
Note 7. Stock-Based Awards (Details) - Stock Options Activity [Line Items]	'	'	'
Canceled (1) (in Shares)	'	'	-1,994,833	[1]
Canceled (1)	'	'	$0.97	[1]
Canceled (1)	'	'	$3.62	[1]
Canceled (1)	'	'	$2.24	[1]
Vested and Expected to Vest [Member]	'	'	'
Note 7. Stock-Based Awards (Details) - Stock Options Activity [Line Items]	'	'	'
Oustanding - Exercise Price Range Minimum	'	'	$0.85
Oustanding - Exercise Price Range Maximum	'	'	$4.88
Granted	'	'	$0.85
Granted	'	'	$4.88
Vested and expected to vest at September 30, 2013 (in Shares)	'	'	4,439,571
Vested and expected to vest at September 30, 2013	'	'	$0.85
Vested and expected to vest at September 30, 2013	'	'	$4.88
Vested and expected to vest at September 30, 2013	'	'	$1.85
Vested and expected to vest at September 30, 2013	'	'	'6 years 36 days
Exercisable at September 30, 2013	'	'	$0.85
Exercisable at September 30, 2013	'	'	$4.88
Exercisable [Member]	'	'	'
Note 7. Stock-Based Awards (Details) - Stock Options Activity [Line Items]	'	'	'
Oustanding - Exercise Price Range Minimum	'	'	$0.85
Oustanding - Exercise Price Range Maximum	'	'	$4.88
Granted	'	'	$0.85
Granted	'	'	$4.88
Vested and expected to vest at September 30, 2013	'	'	$0.85
Vested and expected to vest at September 30, 2013	'	'	$4.88
Exercisable at September 30, 2013 (in Shares)	'	'	3,466,004
Exercisable at September 30, 2013	'	'	$0.85
Exercisable at September 30, 2013	'	'	$4.88
Exercisable at September 30, 2013	'	'	$1.96
Exercisable at September 30, 2013	'	'	'5 years 109 days
[1]	Includes cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari (1,125,000 stock options), and our former VP, Corporate Development and Chief Financial Officer, Katherine L. Wolf (612,458 stock options).

Note_7_StockBased_Awards_Detai2

Note 7. Stock-Based Awards (Details) - Restricted Stock Activity (Restricted Stock [Member], USD $)	6 Months Ended
	Sep. 30, 2013
Restricted Stock [Member]	'
Note 7. Stock-Based Awards (Details) - Restricted Stock Activity [Line Items]	'
Nonvested - Number of Shares	122,044
Nonvested - Weighted Average Grant Price (in Dollars per share)	$2.37
Granted	165,000
Granted (in Dollars per share)	$0.95
Vested	-79,142
Vested (in Dollars per share)	$2.16
Nonvested - Number of Shares	207,902
Nonvested - Weighted Average Grant Price (in Dollars per share)	$1.32

Note_7_StockBased_Awards_Detai3

Note 7. Stock-Based Awards (Details) - Black-Scholes Valuation Assumptions	3 Months Ended		6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Black-Scholes Valuation Assumptions [Abstract]	'	'	'	'
Risk-free interest rate	1.38%	1.02%	1.16%	1.03%
Expected life (in years)	'5 years 36 days	'6 years 146 days	'5 years 6 months	'6 years 146 days
Expected volatility	75.00%	85.00%	80.00%	84.00%

Note_7_StockBased_Awards_Detai4

Note 7. Stock-Based Awards (Details) - Stock-based Compensation Expense (USD $)	3 Months Ended				6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013		Sep. 30, 2012		Sep. 30, 2013		Sep. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'		'		'		'
Allocated stock-based compensation expense	($227)	[1]	$569		$328	[1]	$1,012
Cost of Sales [Member]	'		'		'		'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'		'		'		'
Allocated stock-based compensation expense	12		22		42		69
General and Administrative Expense [Member]	'		'		'		'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'		'		'		'
Allocated stock-based compensation expense	-244	[1]	538	[1]	265	[1]	907	[1]
Research and Development Expense [Member]	'		'		'		'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'		'		'		'
Allocated stock-based compensation expense	$5		$9		$21		$36
[1]	Reflects reversal of stock-based compensation expense of $289 thousand for the cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari.

Note_8_Treasury_Stock_Details_

Note 8. Treasury Stock (Details) - Summary Treasury Stock Activity (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Summary Treasury Stock Activity [Abstract]	'	'	'	'
Number of Shares Repurchased	10,054	17,417	25,525	17,417
Cost (in Dollars)	$10	$24	$28	$24
Weighted Average Purchase Price (in Dollars per share)	$1.06	$1.36	$1.11	$1.36

Note_9_Segment_Information_Det

Note 9. Segment Information (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Segment Reporting [Abstract]	'
Number of Reportable Segments	2
Stock Granted, Value, Share-based Compensation, Forfeited (in Dollars)	$289

Note_9_Segment_Information_Det1

Note 9. Segment Information (Details) - Key Financial Highlights By Reportable Segments (USD $)	3 Months Ended			6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013		Sep. 30, 2012	Sep. 30, 2013		Sep. 30, 2012	Mar. 31, 2013
Segment Reporting Information [Line Items]	'		'	'		'	'
Net sales	$3,968		$3,739	$7,620		$7,135	'
Gross profit	1,195		1,070	2,275		1,983	'
Operating (loss) income	-1,283		-2,621	-3,672		-4,925	'
Interest expense, net	-43		-236	-84		-429	'
Depreciation and amortization	173		202	362		406	'
Stock-based compensation expense	-227	[1]	569	328	[1]	1,012	'
Total assets	10,733		12,530	10,733		12,530	11,377
Expenditures for fixed assets	46		19	46		55	'
Medical [Member]	'		'	'		'	'
Segment Reporting Information [Line Items]	'		'	'		'	'
Net sales	3,399		2,724	6,428		5,220	'
Gross profit	981		746	1,774		1,341	'
Operating (loss) income	-1,345		-2,688	-3,732		-5,032	'
Interest expense, net	-43		-236	-84		-429	'
Depreciation and amortization	170		196	355		393	'
Stock-based compensation expense	-221	[1]	560	309	[1]	960	'
Total assets	11,240		12,751	11,240		12,751	'
Expenditures for fixed assets	46		19	46		55	'
Industrial [Member]	'		'	'		'	'
Segment Reporting Information [Line Items]	'		'	'		'	'
Net sales	569		1,015	1,192		1,915	'
Gross profit	214		324	501		642	'
Operating (loss) income	62		67	60		107	'
Depreciation and amortization	3		6	7		13	'
Stock-based compensation expense	-6	[1]	9	19	[1]	52	'
Total assets	1,333		1,753	1,333		1,753	'
Adjustments [Member]	'		'	'		'	'
Segment Reporting Information [Line Items]	'		'	'		'	'
Stock-based compensation expense	'	[1]	'	'	[1]	'	'
Total assets	($1,840)		($1,974)	($1,840)		($1,974)	'
[1]	Reflects reversal of stock-based compensation expense of $289 thousand for the cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari.

Note_9_Segment_Information_Det2

Note 9. Segment Information (Details) - Reportable Segment Adjustments (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Reportable Segment Adjustments [Abstract]	'	'
Intercompany eliminations	($1,154)	($1,288)
Investment in subsidiaries	-686	-686
Total adjustments	($1,840)	($1,974)

Note_9_Segment_Information_Det3

Note 9. Segment Information (Details) - Reconciliation To Loss Before Provision For Income Taxes (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Reconciliation To Loss Before Provision For Income Taxes [Abstract]	'	'	'	'
Operating loss	($1,283)	($2,621)	($3,672)	($4,925)
Interest expense, net	-43	-236	-84	-429
Other, net	6	-35	2	-40
Debt cost expense	'	-128	'	-272
Loss on extinguishment of debt	'	-1,244	'	-1,244
Loss before provision for income taxes	($1,320)	($4,264)	($3,754)	($6,910)

Note_10_Subsequent_Event_Detai

Note 10. Subsequent Event (Details) (USD $)	60 Months Ended
	Oct. 07, 2018	Oct. 07, 2013
Subsequent Event [Member] | The 2013 Note [Member]	'	'
Note 10. Subsequent Event (Details) [Line Items]	'	'
Debt Instrument, Face Amount	'	$1,000,000
Debt Instrument, Convertible, Conversion Price (in Dollars per share)	'	$0.89
Debt Instrument, Convertible Debt Discount	'	67,000
Subsequent Event [Member]	'	'
Note 10. Subsequent Event (Details) [Line Items]	'	'
Debt Instrument, Convertible, Conversion Price (in Dollars per share)	'	$0.95
The 2013 Note [Member]	'	'
Note 10. Subsequent Event (Details) [Line Items]	'	'
Line of Credit Facility, Maximum Borrowing Capacity	'	$3,500,000
Debt Instrument, Convertible, Remaining Discount Amortization Period	'5 years	'